| Nov 20 |
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
|
| Oct 7 |
Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
|
| Sep 27 |
Pasithea Therapeutics drops 19% on $5M private placement
|
| Sep 26 |
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
| Sep 26 |
Sector Update: Health Care Stocks Mixed Late Afternoon
|
| Sep 26 |
Top Midday Gainers
|
| Sep 26 |
Why Is Pasithea Therapeutics Stock Surging On Thursday?
|
| Sep 26 |
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
|
| Sep 9 |
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
|
| Sep 3 |
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
|
